NPC2 deficiency as a potential target drives malignancy and chemo-resistance in DLBCL
Yining Yuan, Qiqi Wu, Xinyu Li, Peipei Xu · 2026
Read NPC2 deficiency as a potential target drives malignancy and chemo-resistance in DLBCL by Yining Yuan, Qiqi Wu, Xinyu Li, Peipei Xu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13348881.txt.
Description
Diffuse large B-cell lymphoma often resists chemotherapy, and Yuan and co-authors search cell data for the genes behind the failure. A scan of single-cell RNA data flags NPC2, a cholesterol-handling gene whose low levels track with worse patient outcomes. They dim the gene in two lymphoma cell lines and test the results in dishes and in mice.
Dimming NPC2 did not change growth or cell death, but it wrecked the cells' mitochondria, raised harmful oxygen byproducts, and made the cells crawl and invade more. It also made them resist the drug vincristine, in mice as well as in vitro. The authors name NPC2 loss as a driver of aggression and a possible treatment target.
Catalog record
| CREATOR | Yining Yuan, Qiqi Wu, Xinyu Li, Peipei Xu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |